Delving into the Latest Updates on Doxycycline Hyclate with Synapse

Overview

Basic Info

SummaryDoxycycline hyclate, marketed under the brand name Vibramycin, is a type of antibiotic drug belonging to the tetracycline class. The original manufacturer of doxycycline hyclate was Pfizer, who first developed the medication and obtained FDA approval in 1967 for the treatment of various bacterial infections. Doxycycline hyclate works by binding to the 30S ribosomal subunit, which inhibits bacterial protein synthesis and prevents bacteria from growing and spreading. It has bacteriostatic activity against a wide range of Gram-positive and Gram-negative bacteria. This medication is available in different forms, including tablets, capsules, and syrup, for oral administration. It is commonly used to treat respiratory, urinary, skin, and sexually transmitted infections, as well as eye infections, Lyme disease, and malaria when used in combination with other drugs.Doxycycline hyclate, marketed under the brand name Vibramycin, is a type of antibiotic drug belonging to the tetracycline class. The original manufacturer of doxycycline hyclate was Pfizer, who first developed the medication and obtained FDA approval in 1967 for the treatment of various bacterial infections. Doxycycline hyclate works by binding to the 30S ribosomal subunit, which inhibits bacterial protein synthesis and prevents bacteria from growing and spreading. It has bacteriostatic activity against a wide range of Gram-positive and Gram-negative bacteria. This medication is available in different forms, including tablets, capsules, and syrup, for oral administration. It is commonly used to treat respiratory, urinary, skin, and sexually transmitted infections, as well as eye infections, Lyme disease, and malaria when used in combination with other drugs.

Drug Type

Small molecule drug

Synonyms

D-PLEX, DOXY, Doxycycline Hyclate Tabiets

+ [31]

Target

30S subunit

Action

inhibitors

Mechanism

30S subunit inhibitors(30S ribosomal subunit inhibitors)

Therapeutic Areas

Infectious DiseasesDigestive System DisordersEye Diseases+ [4]

Active Indication

AnthraxDysentery, AmebicEye Infections+ [23]

Inactive Indication

Lyme DiseasePeriodontitisRosacea

Originator Organization

Pfizer Inc.

Active Organization

CHARTWELL RX SCIENCES LLCMayne Pharma International Pty Ltd.

PolyPid Ltd.

+ [2]

Inactive Organization

Chartwell Pharma NDA B2 Holdings, LLC.

Den-Mat Holdings LLCPfizer Laboratories (Pty) Ltd.

+ [1]

Drug Highest PhaseApproved

First Approval Date

United States (05 Dec 1967),

Infectious Diseases

RegulationOrphan Drug (European Union), Fast Track (United States), Breakthrough Therapy (United States), Qualified Infectious Disease Product (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC46H58Cl2N4O18

InChIKeyHALQELOKLVRWRI-VDBOFHIQSA-N

CAS Registry24390-14-5

View All Structures (2)

The goal of this clinical trial is to learn if doxycycline taken as 200mg daily for 14 days is effective to treat early stage syphilis. This is different from how doxycycline is typically used for syphilis because the full doxycycline dose will be taken at the same time of day, rather than split up into a twice daily regimen. Lab data support that taking the medication as a single daily dose should be effective as treatment, but it has not been studied clinically. The main question this study aims to answer is:
Is doxycycline taken as a single daily dose of 200mg for 14 days an effective treatment for early syphilis based on a combined outcome of clinical improvement and blood test improvement?
Participants will:
1. Take doxycycline 200mg daily for 14 days
2. Submit oral and rectal swabs that test for syphilis bacteria every other day for 2 weeks, returned by mail
3. Complete 2 brief online surveys over the first 2 weeks
4. Return to the clinic for an interview and blood draw every 3 months for a maximum of 3 study visits, including the first visit
The investigators will compare the percentage of participants in the study who have response to treatment by 6 months to that of persons who have received standard (CDC-recommended) regimens. To do this, the investigators will calculate response percentage estimates following a shot of long-acting penicillin or 14 days of doxycycline 100mg twice daily from 60-person samples from the sexual health program's records.

Start Date03 Mar 2025

Sponsor / Collaborator

University of Washington

CTR20250332

/ Active, not recruitingNot Applicable

盐酸多西环素片随机、开放、交叉设计在中国健康受试者中的生物等效性研究

[Translation] A randomized, open-label, crossover study of the bioequivalence of doxycycline hydrochloride tablets in Chinese healthy subjects

主要目的：以苏州朗科生物技术股份有限公司的盐酸多西环素片为受试制剂；并以Pfizer Japan Inc.持证的盐酸多西环素片为参比制剂，进行生物等效性正式试验。

[Translation]

Main purpose: To conduct a formal bioequivalence study using doxycycline hydrochloride tablets produced by Suzhou Langke Biotechnology Co., Ltd. as the test preparation and doxycycline hydrochloride tablets certified by Pfizer Japan Inc. as the reference preparation.

Start Date03 Mar 2025

Sponsor / Collaborator

Suzhou Lanxite Biotechnology Co., Ltd.

NCT06738407

/ Not yet recruitingPhase 3

Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections Among Adolescent and Young People in the United States

The goal of this open-label, randomized trial is to assess the efficacy of doxycycline prophylaxis in reducing incidences of bacterial sexually transmitted infections (STIs) among people who were assigned female at birth (AFAB) while also evaluating acceptability and antimicrobial resistance in order to inform public health policy.

Start Date15 Feb 2025

Sponsor / Collaborator

Westat, Inc.

[+6]

100 Clinical Results associated with Doxycycline Hyclate

Login to view more data

100 Translational Medicine associated with Doxycycline Hyclate

Login to view more data

100 Patents (Medical) associated with Doxycycline Hyclate

Login to view more data

20,165

Literatures (Medical) associated with Doxycycline Hyclate

01 Dec 2025·Current Genetics

Whole-genome evaluation and prophages characterization associated with genome of carbapenem-resistant Acinetobacter baumannii UOL-KIMZ-24-2

Article

Author: Naqvi, Syed Zeeshan Haider ; Saqib, Anam ; Saleem, Sidrah ; Nawaz, Aniqa ; Ali, Hazrat ; Fatima, Kiran ; Ansari, Farheen ; Ahmad, Mushtaq ; Jahan, Shah ; Hassan, Noor

Carbapenem-resistant Acinetobacter baumannii (CRAB) is an emerging threat to healthcare settings in many countries, principally in South Asia. The current study was aimed to identify, evaluate whole-genome and characterize the prophages in genome of CRAB strain, recovered from patients of Lahore General Hospital, Lahore. More than 200 samples were collected and identified by morphological and biochemical tests. These strains were also subjected to a comprehensive antimicrobial susceptibility evaluation using Kirby-Bauer method and further confirmed as CRAB strains by exploring bla_OXA-51. In addition, the whole-genome evaluation of a Acinetobacter baumannii UOL-KIMZ-24-2 was carried out using various Bioinformatics tools. A total of 150 strains of A. baumannii were recovered and identified in the current study. Among them, 49% strains were found resistant to carbapenem. The bla_OXA-51 was found prevalent in the genome of A. baumannii recovered from medical ICU (38%). In addition, the UOL-KIMZ-24-2 genome analysis based on multilocus sequence typing (MLST) highlighted that UOL-KIMZ-24-2 belonged to ST2 (Pasteur scheme) sequence type. A total of 29 antimicrobial resistance (AMR) genes were present, importantly, bla_OXA-66, bla_OXA-23 and bla_OXA-25. The mobile genetic elements (MGEs) were identified as transposases and belonged to four classes e.g. IS15d1, ISAba24, ISEc29, and ISEc35. A total of 14 virulence factors encoded by 58 different genes were detected in UOL-KIMZ-24-2. In addition, the phage sequences were identified in genome of UOL-KIMZ-24-2, divided into 3 regions. In conclusion, UOL-KIMZ-24-2 contained a mixture of AMR genes, MGEs. prophages sequences and virulence genes.

01 Jul 2025·Separation and Purification Technology

Carbon defects engineered for the formation of highly stable single-atom Pt-N3 bonds: Enhanced electron transfer and efficient peroxymonosulfate activation

Author: Zhong, Haoxiang ; Tan, Xiaofei ; Xu, Piao ; Xu, Jialu ; Hu, Xi ; Yuan, Yuxin ; Zhang, He ; Zhu, Shanshan ; Lai, Cui ; Tang, Chunfang ; Hu, Xinjiang ; Wang, Hui

In this study, a highly stable single-atom Pt-dispersed carbon-deficient graphitic carbon nitride (Pt_SAC/G-CN) photocatalyst with a Pt-N₃ coordination structure was synthesized (supported by X-ray absorbing near-edge structures).The incorporation of Pt atoms altered the electron distribution within the carbon-defective g-C₃N₄ (G-CN), forming a Pt-N₃ coordination structure.This Pt-N₃ coordination structure enhanced the electron transfer efficiency of the photocatalyst, which improved the activation of peroxymonosulfate (PMS) and subsequently facilitated the generation of reactive free radicals.Pt_0.1/G-CN efficiently activated PMS under visible light (λ > 400 nm), resulting in a ciprofloxacin (CIP) degradation of 96.1 % within 150 min.Notably, the turnover frequency (TOF) of Pt_0.1/G-CN is as high as 0.125 min^-1, which is 2-3 orders of magnitude higher than normal Pt-containing catalysts for CIP degradationRadicals quenching experiments and ESR (EPR) indicated that •OH playing crucial roles in the CIP degradation process.Pt_0.1/G-CN exhibited excellent stability and reusability, further emphasizing its practical application potential.Moreover, the role and mechanism of platinum atoms in efficiently activating PMS and degrading quinolone antibiotics under visible light irradiation were also elucidated.These findings provided novel insights into the design of stabilized single-atom metal catalysts for practical use, offering a feasible approach for environmental pollution remediation.

01 Jun 2025·Materials Research Bulletin

Study on the influence of solvent type on the morphology and properties of BiOBr nanosheets through the photodegradation of Doxycycline

Author: Van Huynh, Tien ; Nguyen, Oanh T. K. ; Nguyen, Vi T. T.

The BiOBr photocatalysts with varied morphologies were prepared utilizing the solvothermal approach with solvents.The effects of different solvents on the characteristics and morphol. of BiOBr materials were investigated in depth.The photocatalytic activity of the as-synthesized BiOBr samples was determined by their capacity to degrade Doxycycline (DC) under visible light.The quenching tests revealed that ^•O₂^- and e^- have played a significant role in DC degradationAt a DC concentration of 15 ppm, the BiOBr catalyst, which was produced by dissolving bismuth nitrate in isopropanol, achieved a degrading efficiency of approx. 80%.Reuse studies, together with X-ray diffraction (XRD) and SEM (SEM) examinations of before and after catalysts, validated the reusability and enhanced stability of the as-prepared material.Furthermore, liquid chromatog.-tandem mass spectrometry (LC-MS/MS) was used to determine the degradation routes of DC intermediates, and toxicity studies were carried out using quant. structure-activity relationship (QSAR) modeling.

109

News (Medical) associated with Doxycycline Hyclate

18 Mar 2025

·www.prnewswire.com

Low Doses of Antibiotic Work Just as Well as Higher Ones to Treat Rare Type of Chronic Hair Loss

NEW YORK, March 18, 2025 /PRNewswire/ -- Small amounts of a common antibiotic and anti-inflammatory drug can curb symptoms where a misplaced immune reaction (e.g., autoimmunity) can cause permanent hair loss, a new study shows. This regimen may also come with fewer side effects than higher doses of the medication. Continue Reading Led by researchers at NYU Langone Health, the study explored lymphocytic scarring alopecia, a rare skin condition in which the body's immune cells damage hair follicles, leading to hair loss and scarring. Physicians typically treat this chronic disorder with relatively high doses of the antibiotic doxycycline, often for prolonged periods of time. However, the drug can trigger nausea, vomiting, and rashes and may discourage patients from continuing to take it, the study authors say. As a result, the team set out to determine whether lower doses could work instead. Besides warding off unpleasant side effects, lower doses of the drug may also safeguard gut health. Post this The findings in 241 men and women treated for several forms of lymphocytic scarring alopecia revealed that lower doses (usually 20 milligrams taken twice daily) and higher doses (as much as 100 milligrams taken twice daily) of doxycycline were equally effective. Specifically, the researchers found no significant difference between the two groups on evaluations of scalp inflammation, patients' perception of the severity of their hair loss, and clinical measurements of hair density, hair-shaft diameter, and hairline recession. In addition, while 23% of those on the high-dose regimen experienced common negative side effects of doxycycline, only 12% of those taking smaller doses of the drug did so. Another key finding was that while 25% of the high-dose group stopped taking doxycycline altogether due to gastrointestinal issues, only 16% of the low-dose group stopped treatment due to this side effect. "Our findings suggest that physicians can prescribe lower doses of doxycycline to patients struggling with lymphocytic scarring alopecia without compromising the efficacy and anti-inflammatory benefit of the therapy," said study co-lead author Carli Needle, BA. Needle, a medical student at NYU Grossman School of Medicine, adds that besides warding off unpleasant side effects, lower doses of the drug may also safeguard gut health. Doxycycline, she notes, is known to harm the helpful bacteria that live in the digestive tract and bolster the body's defenses against disease-causing microbes. However, past studies have shown that drug doses below 40 milligrams are less risky for beneficial microbes. The new study is the first to directly compare the efficacy of different-size doses of doxycycline to treat lymphocytic scarring alopecia, says Needle. A report on the findings is publishing March 18 in the Journal of the American Academy of Dermatology. For the study, the research team collected data from electronic medical records of patients with scarring alopecia treated at NYU Langone Health between 2009 and 2023. Of these, about 27% had been prescribed low doses of doxycycline and nearly 73% were on traditional high-dose regimens. Next, the team ran a statistical analysis to compare the two groups. The researchers discounted from their analysis any effects of other medications that commonly accompany this treatment, such as the hair-growth drug minoxidil. According to the authors, a further advantage of reducing doxycycline doses is that experts have linked the drug to the rise of dangerous bacterial populations that can survive antibiotic treatments. Clinicians worldwide are now seeking to combat such antibiotic resistance by limiting how often and in what quantities they prescribe these drugs, a practice called antibiotic stewardship. "Our results offer another avenue for healthcare providers to protect patients from harm caused by unnecessary antibiotic use and address the rise of drug-resistant strains of microbes," said study co-lead author Anna Brinks, BA, a medical student at NYU Grossman School of Medicine. "Alopecia can have a devastating effect on self-image and can lead to social judgment, depression, and anxiety," added study co-senior author Kristen Lo Sicco, MD. "Studies that advance the management of these conditions are critical to addressing not only hair loss itself, but also the psychological and social consequences that accompany it." Lo Sicco, an associate professor in the Ronald O. Perelman Department of Dermatology at NYU Grossman School of Medicine, says that the researchers next plan to repeat their work in a larger and more diverse group, as the study patients were mostly White. In addition, she says the team intends to explore the triggers that cause lymphocytic scarring alopecia, which remain poorly understood. Study funding was provided by NYU Langone Health. In addition to Needle, Brinks, and Lo Sicco, other NYU Langone researchers involved in the study are Akshay Pulavarty, MD, MPH; Caitlin Kearney, BS; Ambika Nohria, BA; Deesha Desai, BS; and Jerry Shapiro, MD. About NYU Langone Health NYU Langone Health is a fully integrated health system that consistently achieves the best patient outcomes through a rigorous focus on quality that has resulted in some of the lowest mortality rates in the nation. Vizient, Inc., has ranked NYU Langone the No. 1 comprehensive academic medical center in the country for three years in a row, and U.S. News & World Report recently placed nine of its clinical specialties among the top five in the nation. NYU Langone offers a comprehensive range of medical services with one high standard of care across seven inpatient locations, its Perlmutter Cancer Center, and more than 300 outpatient locations in the New York area and Florida. With $14.2 billion in revenue this year, the system also includes two tuition-free medical schools, in Manhattan and on Long Island, and a vast research enterprise with over $1 billion in active awards from the National Institutes of Health. Media Inquiries: Shira Polan Phone: 212-404-4279 [email protected] SOURCE NYU Grossman School of Medicine and NYU Langone Health WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical Result

11 Mar 2025

·www.globenewswire.com

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Last Patient Enrolled Following Positive Recommendation by DSMB to Conclude Enrollment of Phase 3 Trial at 800 Patients; Top-line Results Expected by End of Q2 2025 and, if Positive, Expected to be Followed by Submission of an NDA to the FDA Leveraging the Company’s Fast-Track and Breakthrough Therapy DesignationsPETACH TIKVA, Israel, March 11, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced the successful completion of enrollment in the SHIELD II Phase 3 trial for D-PLEX100 for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery. This milestone follows recommendation by the independent Data Safety Monitoring Board (“DSMB”), which, after analyzing unblinded efficacy data from the first 430 enrolled patients in the trial, recommended concluding the study upon enrollment of 800 patients, the lowest sample size reassessment stop after the minimum planned number of patients. The Company anticipates reporting top-line results by the end of the second quarter of 2025. If the Phase 3 data are positive, PolyPid expects to submit a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”), leveraging the FDA’s Fast Track and Breakthrough Therapy designations. “We are excited to reach another critical milestone in our ongoing SHIELD II Phase 3 trial, reinforcing the positive trajectory of D-PLEX100’s development,” said Dikla Czaczkes Akselbrad, PolyPid’s Chief Executive Officer. “With top-line data expected by the end of the second quarter of 2025, we are preparing to engage with the FDA for a pre-NDA meeting to discuss a rolling NDA submission under the Breakthrough Therapy designation. Importantly, we remain in active discussions with multiple potential partners for the commercialization of D-PLEX100 in various regions, starting with the U.S.” About SHIELD IISHIELD II (Surgical site Hospital acquired Infection prEvention with Local D-PLEX) is a prospective, multinational, randomized, double blind Phase 3 trial designed to assess the efficacy and safety of D-PLEX100 administered concomitantly with standard of care (“SoC”), which includes prophylactic systemic antibiotics, compared to SoC alone arm, in the prevention of post abdominal-surgery incisional infection in patients undergoing abdominal colorectal surgeries with large incisions. The primary endpoint of the trial is measured by the proportion of subjects with either a surgical site infection (“SSI”) event as determined by a blinded and independent adjudication committee, reintervention, or mortality for any reason within 30 days post-surgery. Patient safety will be monitored for an additional 30 days. The trial will enroll patients in centers in the United States, Europe and Israel. About D-PLEX100D-PLEX100, PolyPid’s lead product candidate, is designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site to prevent SSIs. Following the administration of D-PLEX100 into the surgical site, the PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, enabling a prolonged and continuous release of the broad-spectrum antibiotic doxycycline, resulting in a high local concentration of the drug for a period of 30 days for the prevention of SSIs, with additional potential to prevent SSIs caused by antibiotic-resistant bacteria at the surgical site. D-PLEX100 received Breakthrough Therapy, Fast Track and Qualified Infectious Disease Product (QIDP) designations from the FDA for the prevention of SSIs in patients undergoing abdominal colorectal surgery. D-PLEX100 is currently in Phase 3 SHIELD II trial for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery with large incisions. About PolyPidPolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma. For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn. Forward-looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the timing of anticipated reporting of top-line results, that upon potential positive Phase 3 data, the Company anticipates submission of an NDA leveraging the advantages of Fast Track and Breakthrough Therapy designations, the intention to pursue a pre-NDA meeting with the FDA to discuss a rolling NDA submission, and discussions with multiple potential partners for the commercialization of D-PLEX100 in various regions, starting with the U.S. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission, including, but not limited to, the risks detailed in the Company’s Annual Report on Form 20-F filed on February 26, 2025. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites. Contacts: PolyPid Ltd. Ori WarshavskyCOO – US908-858-5995IR@Polypid.com Investors:Brian RitchieLifeSci Advisors212-915-2578BRitchie@lifesciadvisors.com

Phase 3Fast TrackNDAQualified Infectious Disease ProductBreakthrough Therapy

30 Jan 2025

·www.globenewswire.com

PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

PETACH TIKVA, Israel, Jan. 30, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company’s management will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference taking place virtually on February 11 - 12, 2025. Oppenheimer 35th Annual Healthcare Life Sciences Conference PolyPid’s presentation will be available on-demand beginning on Wednesday, February 12, 2025 at 11:20 AM Eastern Time and for 365 days after via the conference platform or using the following link. The PolyPid management team will participate in one-on-one investor meetings during this event. Investors interested in meeting with PolyPid at the conference should contact their Oppenheimer representative. About PolyPid PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma. For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn. Contacts: PolyPid Ltd. Ori Warshavsky COO – US 908-858-5995 IR@Polypid.com Investors: Brian Ritchie LifeSci Advisors 212-915-2578 britchie@lifesciadvisors.com

Phase 3

100 Deals associated with Doxycycline Hyclate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Doxycycline Hyclate	J01AA02 A01AB22	DB00254

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Dysentery, Amebic	United States	Mayne Pharma International Pty Ltd.	11 Apr 2013
Inhalation Anthrax	United States	Mayne Pharma International Pty Ltd.	11 Apr 2013
Sexually Transmitted Diseases	United States	Mayne Pharma International Pty Ltd.	11 Apr 2013
Conjunctivitis, Inclusion	United States	Mayne Pharma International Pty Ltd.	06 May 2005
Gram-Negative Bacterial Infections	United States	Mayne Pharma International Pty Ltd.	06 May 2005
Lymphogranuloma Venereum	United States	Mayne Pharma International Pty Ltd.	06 May 2005
non-gonococcal urethritis (NGU)	United States	Mayne Pharma International Pty Ltd.	06 May 2005
Pneumonia, Mycoplasma	United States	Mayne Pharma International Pty Ltd.	06 May 2005
Psittacosis	United States	Mayne Pharma International Pty Ltd.	06 May 2005
Q Fever	United States	Mayne Pharma International Pty Ltd.	06 May 2005
Relapsing Fever	United States	Mayne Pharma International Pty Ltd.	06 May 2005
Respiratory Tract Infections	United States	Mayne Pharma International Pty Ltd.	06 May 2005
Rickettsia Infections	United States	Mayne Pharma International Pty Ltd.	06 May 2005
Rocky Mountain Spotted Fever	United States	Mayne Pharma International Pty Ltd.	06 May 2005
Spotted Fever Group Rickettsiosis	United States	Mayne Pharma International Pty Ltd.	06 May 2005
Trachoma	United States	Mayne Pharma International Pty Ltd.	06 May 2005
Typhus, Endemic Flea-Borne	United States	Mayne Pharma International Pty Ltd.	06 May 2005
Urethritis or cervicitis: chlamydia trachomatis	United States	Mayne Pharma International Pty Ltd.	06 May 2005
Infectious Diseases	Japan	Pfizer Japan, Inc.	25 Apr 1975
Bacterial Infections	China	-	-

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bacterial Infections	NDA/BLA	Canada	SteriMax, Inc.	01 Jan 2025
Postoperative infection	Phase 3	Israel	PolyPid Ltd.	24 Jun 2020
Surgical Wound Infection	Phase 3	United States	PolyPid Ltd.	17 Dec 2019
Surgical Wound Infection	Phase 3	Israel	PolyPid Ltd.	17 Dec 2019
Postoperative infection	Discovery	Croatia	PolyPid Ltd.	24 Jun 2020
Postoperative infection	Discovery	Czechia	PolyPid Ltd.	24 Jun 2020
Rosacea	Discovery	United States	CollaGenex Pharmaceuticals, Inc.	01 Jun 2002

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04233424 (SHIELD 1, Literature) Manual	Phase 3	Surgical Wound Infection	-	D-PLEX 100+SOC	(lvflcjdpbf) = nrtnvffzrt tmyeofdrso (bkijcynpcc )	Positive	21 Oct 2024
				SOC	(lvflcjdpbf) = lpvqjabptg tmyeofdrso (bkijcynpcc )
NCT05399290 (CTgov)	Phase 4	Acne Vulgaris	22	Doxycycline Hyclate (100 mg Standard Dose Doxycycline BID)	ewqrsnfvke(rlzmdboqna) = sucsjjhzzt hslybhvsmc (kkriontoek, gwhyxrocdx - uzqlvjimdq) View more	-	03 Apr 2023
				Doxycycline Hyclate (20 mg Sub-antimicrobial Dose Doxycycline BID)	ewqrsnfvke(rlzmdboqna) = agihibdaag hslybhvsmc (kkriontoek, tbiwkecbql - mzpiqtnbqk) View more
NCT02899000 (CTgov)	Phase 4	Acne Vulgaris	186	Oral doxycycline hyclate+Adapalene 0.3% / benzoyl peroxide 2.5% emulsion gel	oiykmxhbat(seyofheztj) = vxthgmcskw yzdgglsjrj (deytueooeb, idkpcnzwcw - diohbzwrvr) View more	-	09 Dec 2022
NCT04233424 (SHIELD I \| D-PLEX 311, Corporate Publications) Manual	Phase 3	Surgical Wound Infection	423	Standard of Care+D-PLEX100	oxuhafxaaq(bepwmfqvrs): difference = -54, P-Value = <0.0032	Positive	02 Sep 2022
				Standard of Care
NCT03633123 (Pubmed) Manual	Phase 2	Surgical Wound Infection	179	SoC+D-PLEX 100	mcdytiouha(xfvossemcq) = rooylomfhp aoqbokevzv (vlgxbfqjhn )	Positive	01 Sep 2022
				SoC	mcdytiouha(xfvossemcq) = wkvijdkzgw aoqbokevzv (vlgxbfqjhn )
NCT03075891 (ANSWER, CTgov)	Phase 4	Rosacea	273	Doxycycline 40 mg MR (30 mg Immediate Release & 10 mg Delayed Release beads) capsules+Ivermectin 1% cream (Ivermectin 1% Cream + Doxycycline 40 mg MR Capsules)	xtoonpdeub(azmyczxggx) = eldboiajui wzbxwkpysw (bekulupqxr, kirkmdnspz - ujnnynifgu) View more	-	29 Nov 2019
				Oral placebo capsules+Ivermectin 1% cream (Ivermectin 1% Cream + Oral Placebo Capsules)	xtoonpdeub(azmyczxggx) = nabrbglyqt wzbxwkpysw (bekulupqxr, gaaldlvfoa - wewsxbccip) View more
NCT00246740 (CTgov)	Phase 2	Reperfusion Injury	56	Placebo Oral Tablet (Placebo Oral Tablet)	qqxfzvzqno(tdtoghhsfa) = ohopvzlrww jpgdzivjrn (mcgmaadjql, avcxbitgga - cvxadonclk) View more	-	15 Dec 2017
				Periostat (Periostat)	qqxfzvzqno(tdtoghhsfa) = tgdyuwbrzo jpgdzivjrn (mcgmaadjql, izkxdcklcr - wvinaunklx) View more
NCT01113931 (CTgov)	Phase 3	Chlamydia trachomatis infection	495	Doxycycline Hyclate (Doxycycline Hyclate)	(attawpesot) = eaugwmvzhv wrqswnepsf (zkazhsbwyn, ujpdbewzqq - zdqyjntoun) View more	-	27 Jan 2012
				Vibramycin (Vibramycin)	(attawpesot) = fwagqdcixc wrqswnepsf (zkazhsbwyn, noyqhblrms - rpepanbtbs) View more
NCT00635609 (CTgov)	Phase 4	Acne Vulgaris	93	Doxycycline Hyclate (Doryx) (Doxycycline Hyclate (Doryx) Delayed-release Tablets)	jaqyfbhyre(stuzjdyuvr) = dwdpiujyak onqkdhujlk (oddelysxfe, pjhtxbpibe - qandpmvvey) View more	-	30 Dec 2009
				Doxycycline Hyclate (Doxycycline Hyclate Immediate-release Tablets)	jaqyfbhyre(stuzjdyuvr) = xnbbvlxhlu onqkdhujlk (oddelysxfe, ocnoubkdjm - chfctlbnju) View more